JSJonathan E. Shoag

Jonathan E. Shoag

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan E. Shoag has a total of 260 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick Lewicki

    Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA

    12 shared publications
  • Camilo Arenas-Gallo

    Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    9 shared publications
  • Christopher E. Barbieri

    Department of Urology, Weill Cornell Medicine, New York, USA

    7 shared publications
  • Spyridon P. Basourakos

    Department of Urology, Mayo Clinic Rochester, Minnesota. USA

    7 shared publications
  • Stephen Rhodes

    Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH

    7 shared publications
  • Camilo Arenas-Gallo

    Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio

    6 shared publications

Latest Publications

  • Open Access

    Is “Full Access to All the Data” Necessary? The TriNetX Platform and Author Accountability

    by Stephen Rhodes, Fredrick Schumacher, Jonathan Shoag

    All reports containing original data in JAMA journals must include a statement that at least one author "had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis." Similar attestations are required by many other journals. Over the past several years, a rapidly increasing number of articles have been published, including many (up to 100) in the JAMA family of journals [1], for which this statement is false (yet still made). These studies use the TriNetX platform, a point-and-click dashboard on which users can create cohorts and run a limited selection of analyses.

  • Open Access

    Individual income and race-associated differences in prostate cancer mortality in a statewide registry

    by Alec Zhu, Stephen Rhodes, Bashir Al Hussein Al Awamlh, Randy A Vince, Nicholas Zaorsky, Daniel E Spratt, Camilo Arenas Gallo, Anyull Dayanna Bohorquez Caballero, Mollie Goldman, Jonathan E Shoag

    Background: Prior studies evaluating racial disparities in cancer outcomes used regional measures of deprivation when accounting for socioeconomic status, which lack granularity. We evaluated differences in prostate cancer mortality between Black and White men using individual home prices in addition to regional metrics to understand the impact of individual wealth on prostate cancer outcomes. Methods: Individuals diagnosed with prostate cancer between January 2004 and December 2016 in the Ohio Cancer Incidence Surveillance System were included. Individual home addresses were linked to the Area Deprivation Indices and home prices using data from an online real estate marketplace. Using inverse probability weighting to balance patient characteristics, we assessed differences in prostate cancer–specific mortality or other-cause mortality between Black and White men after accounting for clinical characteristics and social determinants of health (insurance, area deprivation, and home price). Results: We identified 70 660 (85%) White and 12 192 (15%) Black men with prostate cancer. Black race was associated with a higher risk of prostate cancer–specific mortality in models that adjusted for age and year at diagnosis (subdistribution hazard ratio = 1.45, 95% CI = 1.45 to 1.57) and with the addition of cancer variables (subdistribution hazard ratio = 1.16, 95% CI = 1.06 to 1.26). In models that incorporate social determinants of health, however, rates of prostate cancer–specific mortality and other-cause mortality were not statistically significantly higher for Black men (subdistribution hazard ratios = 1.10, 95% CI = 0.98 to 1.24, and 1.02, 95% CI = 0.95 to 1.09), respectively. Conclusions: After accounting for clinical characteristics and social determinants of health at the individual level, Black men were not at increased risk of prostate cancer mortality relative to White men.

  • Open Access

    Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules

    by Alexandre Pellan Cheng, Itai Rusinek, Aaron Sossin, Adam J. Widman, Eti Meiri, Gat Krieger, Ori Hirschberg, Doron Shem Tov, Shlomit Gilad, Ariel Jaimovich, et al.

    Distinguishing real biological variation in the form of single-nucleotide variants (SNVs) from errors is a major challenge for genome sequencing technologies. This is particularly true in settings where SNVs are at low frequency such as cancer detection through liquid biopsy, or human somatic mosaicism. State-of-the-art molecular denoising approaches for DNA sequencing rely on duplex sequencing, where both strands of a single DNA molecule are sequenced to discern true variants from errors arising from single stranded DNA damage. However, such duplex approaches typically require massive over-sequencing to overcome low capture rates of duplex molecules. To address these challenges, we introduce paired plus-minus sequencing (ppmSeq) technology, in which both DNA strands are partitioned and clonally amplified on sequencing beads through emulsion PCR. In this reaction, both strands of a double-stranded DNA molecule contribute to a single sequencing read, allowing for a duplex yield that scales linearly with sequencing coverage across a wide range of inputs (1.8-98 ng). We benchmarked ppmSeq against current duplex sequencing technologies, demonstrating superior duplex recovery with ppmSeq, with a rate of 44%±5.5% (compared to ∼5-11% for leading duplex technologies). Using both genomic as well as cell-free DNA, we established error rates for ppmSeq, which had residual SNV detection error rates as low as 7.98×10 -8 for gDNA (using an end-repair protocol with dideoxy nucleotides) and 3.5×10 -7 ±7.5×10 -8 for cell-free DNA. To test the capabilities of ppmSeq for error-corrected whole-genome sequencing (WGS) for clinical application, we assessed circulating tumor DNA (ctDNA) detection for disease monitoring in cancer patients. We demonstrated that ppmSeq enables powerful tumor-informed ctDNA detection at concentrations of 10 -4 across most cancers, parts per million sensitivity in cancers with high mutation burden, and further increased sensitivity with higher sequencing depth. We then leveraged genome-wide trinucleotide mutation patterns characteristic of urothelial (APOBEC3-related and platinum exposure-related signatures) and lung (tobacco-exposure-related signatures) cancers to perform tumor-naive ctDNA detection, showing that ppmSeq can identify a disease-specific signal in plasma cell-free DNA without a matched tumor, and that this signal correlates with imaging-based disease metrics. Altogether, ppmSeq provides an error-corrected, cost-efficient and scalable approach for high-fidelity WGS that can be harnessed for challenging clinical applications and emerging frontiers in human somatic genetics where high accuracy is required for mutation identification.


  • Increasing Utilization of Sedation for Prostate Biopsies: National Trends, Predictors, and Patient Cost

    by Camilo Arenas-Gallo, Mollie Goldman, Jack C. Millot, Jacob McCann, Anyull D. Bohorquez-Caballero, Stephen Rhodes, Vishu Chandrasekhar, Michael Callegari, Leo Puhalla, Adam Calaway, et al.


  • Open Access

    Utilization, Acute Complications, and Delays in Treatment Associated With Rectal Spacers for Prostate Cancer Radiotherapy

    by Jack C. Millot, Adithya Balasubramanian, Lauren Chew, Gal Wald, Camilo Arenas-Gallo, Edward Zhang, Jacob McCann, Leo D. Dreyfuss, Stephen Rhodes, Patrick Lewicki, et al.


  • Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men

    by Angela Y. Jia, Yilun Sun, Maitry Patel, Atallah Baydoun, Randy A. Vince, Jonathan E. Shoag, Jason R. Brown, Pedro C. Barata, Matthew J. Schipper, Robert T. Dess, et al.

    PURPOSE: The 22-gene Decipher genomic classifier (GC) (22-gene GC) is the only gene expression test with National Comprehensive Cancer Network (NCCN) level 1 evidence for localized prostate cancer (PCa) treatment decision making. It is unclear whether other commercial signatures—Genomic Prostate Score (GPS) or Prolaris (cell cycle progression [CCP])—correlate sufficiently to explain differences in evidence strength. This study assesses correlation between these three classifiers on a per-patient basis by performing a cross-comparison of these signatures in a large cohort of patients diagnosed with PCa. MATERIALS AND METHODS: Primary PCa biopsy samples underwent whole-transcriptome gene expression microarray analysis. 22-gene GC scores were calculated using the commercially locked model. To reduce bias, GPS and CCP signatures were retrained for prediction of metastasis to harmonize end points. Pearson correlations and linear regressions (univariable/multivariable) adjusting for age, grade group, prostate-specific antigen (PSA), and T stage were calculated between signatures. RESULTS: Among 50,881 patients (median age 68 years, median PSA 6.2 ng/mL), 60% were NCCN intermediate-risk. The GPS-derived and CCP-derived models had poor goodness-of-fit to 22-gene GC ( R 2 = 0.36 and 0.32, respectively). Multivariable analysis adjusting for clinical factors showed similar results. Given the many variables that may contribute to or correlate with the 22-gene GC, a multivariable R 2 analysis was performed to assess how much of the variation could be attributed to known factors. A variance analysis revealed approximately 60% of 22-gene GC variation remained unexplained. GPS-derived and CCP-derived models accounted for 24.7% and 22.7% of variance, respectively, with additional contributions from Gleason score. CONCLUSION: Correlation between 22-gene GC and either GPS-derived or CCP-derived signatures is minimal to moderate. These tests are not interchangeable, and their use should be guided by the specific evidence supporting each signature.


  • Incidence and prevention strategies for postprostate biopsy infections in the United States from 2012 to 2021

    by Adithya Balasubramanian, Gal Wald, Stephen Rhodes, Aaron Gurayah, Camilo Arenas-Gallo, Jack Millot, Leo Dreyfuss, Jonathan Shoag, Patrick Lewicki


  • AI Streamlines Prostate Pathology Data Extraction

    by Spyridon P. Basourakos, Jonathan E. Shoag


  • Open Access

    Chemotherapy and the somatic mutation burden of sperm

    by Shany Picciotto, Camilo Arenas-Gallo, Amos Toren, Ruty Mehrian-Shai, Bryan Daly, Stephen Rhodes, Megan Prunty, Ruolin Liu, Anyull Bohorquez, Marta Grońska-PęSki, et al.

    Many chemotherapeutic agents impair cancer growth by inducing DNA damage. The impact of these agents on mutagenesis in normal cells, including sperm, is largely unknown. Here, we applied high-fidelity duplex sequencing to 94 samples from 36 individuals exposed to diverse chemotherapies and 32 controls. We found that in many of the sperm samples from men exposed to chemotherapy, the mutation burden was elevated as compared with controls and the expected burden based on trio studies, with 1 patient having a more than 10-fold increase over that expected for age. Saliva from this same individual also had a markedly higher mutation burden. We then validated this finding using other tissues, also finding an increased mutation burden in the blood and liver of many patients exposed to chemotherapy as compared with unexposed controls. Similarly, mice treated with 3 cycles of cisplatin had an increased mutation burden in sperm but also in the liver and hematopoietic progenitor cells. These results suggest an association between cancer therapies and mutation burden, with implications for counseling patients with cancer considering banking sperm before therapy and for cancer survivors considering the trade-offs of using banked sperm as compared with conceiving naturally.


  • Open Access

    Direct measurement of the male germline mutation rate in individuals using sequential sperm samples

    by Jonathan E. Shoag, Amoolya Srinivasa, Caitlin A. Loh, Mei Hong Liu, Emilie Lassen, Shana Melanaphy, Benjamin M. Costa, Marta Grońska-Pęski, Nisrine T. Jabara, Shany Picciotto, et al.

    Mutations that accumulate in the human male germline with age are a major driver of genetic diversity and contribute to genetic diseases. However, aging-related male germline mutation rates have not been measured directly in germline cells (sperm) at the level of individuals. We developed a study design in which we recalled 23 sperm donors with prior banked samples to provide new sperm samples. The old and new sequential sperm samples were separated by long timespans, ranging from 10 to 33 years. We profiled these samples by high-fidelity duplex sequencing and demonstrate that direct high-fidelity sequencing of sperm yields cohort-wide mutation rates and patterns consistent with prior family-based (trio) studies. In every individual, we detected an increase in sperm mutation burden between the two sequential samples, yielding individual-specific measurements of germline mutation rate. Deep whole-genome sequencing of sequential sperm samples from two individuals followed by targeted validation measured remarkably stable mosaicism of clonal mutations that likely arose during embryonic and germline development, suggesting that age did not substantially impact the diversity of spermatogonial stem cell pools in these individuals. Our application of high-fidelity and deep whole-genome sequencing to sequential sperm samples provides insight into aging-related mutation processes in the male germline.